Dry Eye Syndrome Treatment Market worth USD xx million by 2025Posted by venkatakiran on October 3rd, 2019 Dry Eye Syndrome Treatment Market Size and Growth Rate:
“The Global Dry Eye Syndrome Treatment Market is expected to reach US$ xx Mn by 2023 owing to growth in R&D for the development of newer therapeutis”
Dry Eye Syndrome Treatment Market Growth Drivers and Restraints: The global dry eye syndrome treatment market is expected to reach US$ xx Mn by 2023. Dry eye syndrome is an ocular disease, which is caused by the lack of tear fluid to lubricate the eyes. This further leads to problem in vision, the tear film become instable, and discomfort causes potential damage to the ocular surface. The factors which are streaming the growth of this market are rise in geriatric population, surge in prevalence of ophthalmic diseases, vitamin A deficiency, etc. Usage of several medications can also lead to the dry eye syndrome such as hormone replacement therapy, blood pressure medication, antihistamines, and antidepressants, etc. Dry eye syndrome is a common eye disease, which affects 5–34% of people to some degree and among older people it affects up to 70%. On the flip side expiry of the blockbuster drug patients hamper the growth of global dry eye syndrome treatment market. Moreover taking precautions by controlling the environmental factors such as avoiding smoke and dust, heater, air conditioners, and wearing glasses all the time can also lead to reduction in treatment therapy. Browse More Details of the report @https://www.precisionbusinessinsights.com/market-reports/global-dry-eye-syndrome-treatment-market/ Evaporative dry eye syndrome Dominate the Global Dry Eye Syndrome Treatment Market Based on the disease type, global dry eye syndrome treatment market is segmented into evaporative dry eye syndrome and aqueous dry eye syndrome. Evaporative dry eye syndrome dominated the global dry eye syndrome treatment market due to the increasing its prevalence among the geriatric population. It is the most common form of dry eye syndrome in which the glands become block, and tears won’t contain the right amount of oil to keep them from evaporating.
North America Leads the Global Dry Eye Syndrome Treatment Market
PBI’s global dry eye syndrome treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global dry eye syndrome treatment market through 2014-2018 and expected to dominate over 2019-2025 owing to increase in their use of medications such as antihistaminics, antidepressants, and pain relievers which contribute to increased risk of dry eye syndrome over there. Approximately 1 to 4 million adults (age 65-84) in the USA suffers from dry eye syndrome. Additionally, disposable income and healthcare expenditure are contributing in the market growth of dry eye syndrome in North America. Europe dry eye syndrome treatment market accounted for a significant share in global dry eye syndrome treatment market due to its increase in its prevalence among the European population, development in healthcare infrastructure, and increase in disposable income in countries such as U.K, Germany etc. Asia Pacific dry eye syndrome treatment market expected to grow significant growth rate due to their rise in geriatric population majorly in India and China, in China it affects about 17% of the population. Emerging economies, increase in the prevalence of dry eye syndrome, development of healthcare infrastructure, and technological advancements bolster the growth of dry eye syndrome treatment market in APAC region. Launch of newer products, and strategic alliances are the key strategies adopted by market players
Global dry eye syndrome treatment market further reveals that the key player’s increasingly adopting strategies such as launch of newer products, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, in March 2017, Novaliq signed an agreement with AFT Pharmaceuticals for the commercialization of NovaTears in New Zealand and Australia. Furthermore, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease. Key player’s profiles in the report are Novartis AG (Switzerland), Novaliq GmbH (Germany), Nicox (France), Mimetogen Pharmaceuticals (U.S.), Allergan (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Otsuka Holdings Co., Ltd. (Japan), Auven Therapeutics (U.S.), AFT Pharmaceuticals (New Zealand), I-Med Pharma, Inc. (Canada), and Sun Pharmaceuticals Industries Ltd. (India). Avail Sample of the report for more information @ https://www.precisionbusinessinsights.com/request-sample?product_id=15843 Detailed Segmentation of Dry Eye Syndrome Treatment Market:
By Treatment
o Preservative-Free Drops o Oily Tear Eye Drops o Eye Ointments
o Corticosteroids o Tetracyclines Oral
By Disease Type
By Distribution Channel
Geography
o North America o Europe o Asia-Pacific o Latin America o Middle East and Africa (MEA)
About Us: Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. Contact Us: Shreya Paul Senior Business Development Executive Email @ shreya@precisionbusinessinsights.com Call @ +1-866-598-1553 Precision Business Insights Like it? Share it! More by this author |